Novel aspects of factor XIII deficiency

Muszbek, László and Bagoly, Zsuzsa and Cairo, Andrea and Peyvandi, Flora (2011) Novel aspects of factor XIII deficiency. Current opinion in hematology, 18 (5). pp. 366-72. ISSN 1065-6251, ESSN: 1531-7048

Preview

Text 159.Novel aspects of factor XIII deficiency.pdf Download (281kB) | Preview

Abstract

PURPOSE OF REVIEW Here we review recent developments concerning the diagnosis, classification and treatment of factor XIII (FXIII) deficiency and new findings related to the pathogenesis of the disease. RECENT FINDINGS Most recently, the International Society on Thrombosis and Haemostasis, Scientific and Standardization Committee published a guideline for the diagnosis and classification of FXIII deficiencies. Since 2009, three novel mutations causing severe bleeding diathesis were discovered in the FXIII-A gene and one in the FXIII-B gene. A newly described FXIII-A deficiency was of the extremely rare qualitative type II deficiency. The first well established founder effect was reported for a causative FXIII-A mutation. More than a quarter of all FXIII-A deficiencies are due to autoantibody, among them the first case of deficiency caused by anti-FXIII-B autoantibody was reported in the last 2 years. The safety and effectiveness of plasma FXIII concentrate for prophylaxis and treatment is now well established. The new recombinant FXIII product is currently in phase III clinical trial and the preliminary data are promising. SUMMARY FXIII deficiency is considered the most underdiagnosed bleeding diathesis. The recommended algorithm for its diagnosis and classification could improve the diagnostic efficiency. The preferred choice for substitution therapy is FXIII concentrate (plasma-derived or, in the future, recombinant).

Actions (login required)

Edit Item